Table 1

Demographics, disease characteristics and concomitant SLE medications at baseline

BLISS-52 (n=865)BLISS-76 (n=819)Pooled data (n=1684)
Sex, female, %94.993.394.1
Age, years, mean±SD35.5±11.140.2±11.537.8±11.5
Ethnicity, %
Disease characteristics
SLE disease duration, years, mean±SD5.31±5.327.52±7.106.38±6.35
SELENA–SLEDAI score, mean±SD9.75±3.769.67±3.759.71±3.76
BILAG organ domain involvement
 ≥1 A or ≥2 B scores, %58.363.560.8
 ≥1 A score, %
Medication, %
 ≤7.5 mg/day*26.630.228.3
 >7.5 mg/day*69.445.958.0
Other immunosuppressive agents42.255.648.7
HMG CoA reductase inhibitors8.210.17.6
  • * Prednisone or prednisone-equivalent dose.

  • 0.7% of patients received oral cyclophosphamide, 0.4% mizorbine and 0.2% thalidomide.

  • BILAG, British Isles Lupus Assessment Group; HMG CoA, 3-hydroxy-3-methyl-glutaryl–coenzyme A; NSAID, non-steroidal anti-inflammatory agent; SELENA–SLEDAI, Safety of Oestrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus.